Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
Azitra completed Cohort 1 of its Phase 1/2 trial of ATR04-484 for EGFR inhibitor-associated skin rash, with the safety review committee clearing the study to proceed to Cohort 2. Cohort 1 enrolled seven patients; Cohort 2 is expected to enroll approximately 24 patients receiving once-daily 4g application for 28 days, at six sites including MD Anderson and Yale. ATR-04 holds FDA Fast Track designation for an indication affecting roughly 150,000 U.S.
Key figures
- Drug Name
- ATR-04 (ATR04-484)
- Phase Of Trial
- Phase 1/2
- Clinical sites
- 6
- Cohort1 patients
- 7
- Egfri rash incidence
- 50-80%
- Cohort2 expected enrollment
- 24
- Us annual patient population
- 150000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.